Bacillus calmette-guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy

European Urology

Volumn 66, Issue 4, 2014, Pages 677-688

  Rentsch, Cyrill A ^a,b   Birkhäuser, Frédéric D ^c   Biot, Claire ^b,d,e   Gsponer, Joël R ^a,b   Bisiaux, Aurélie ^b,d   Wetterauer, Christian ^a,b   Lagranderie, Micheline ^b   Marchal, Gilles ^b   Orgeur, Mickael ^b   Bouchier, Christiane ^b   Bachmann, Alexander ^a   Ingersoll, Molly A ^b,d,f   Brosch, Roland ^b   Albert, Matthew L ^b,d,f   Thalmann, George N ^c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b INSTITUT PASTEUR   (France)

^c UNIVERSITY OF BERN   (Switzerland)

^d INSERM   (France)

^e PSL RESEARCH UNIVERSITY   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Animal; BCG Connaught; BCG Tice; BCG vaccine; Flow cytometry; Immunotherapy; Intravesical drug administration; Models; Randomized controlled trial; Urinary bladder neoplasms

Indexed keywords

BCG VACCINE; GENOMIC DNA; BACTERIAL DNA; BCG CONNAUGHT;

ADULT; AGED; ANIMAL EXPERIMENT; ARTICLE; BACTERIUM CULTURE; BLADDER; CANCER IMMUNOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYTOMETRY; DISEASE SPECIFIC SURVIVAL; DNA SEQUENCE; DRUG EFFICACY; DYSURIA; FEMALE; HEMATURIA; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INTRAVENOUS UROGRAPHY; LYMPHOID TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUSE; MYCOBACTERIUM BOVIS BCG; NOCTURIA; NON MUSCLE INVASIVE BLADDER CANCER; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; STRAIN DIFFERENCE; TH1 CELL; TREATMENT RESPONSE; ANIMAL TISSUE; BACTERIAL GENOME; BACTERIAL STRAIN; BACTERIUM DETECTION; BODY TEMPERATURE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; EXPERIMENTAL STUDY; FLOW CYTOMETRY; GENE SEQUENCE; IN VIVO STUDY; LYMPHOCYTE MIGRATION; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; SEPSIS; SIDE EFFECT; TREATMENT OUTCOME; TUMOR IMMUNITY; ANIMAL; C57BL MOUSE; CARCINOMA, TRANSITIONAL CELL; CLASSIFICATION; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; IMMUNOTHERAPY; INTRAVESICAL DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MORTALITY; NONPARAMETRIC TEST; PATHOLOGY; PROCEDURES; RISK ASSESSMENT; SURVIVAL; TUMOR RECURRENCE; URINARY BLADDER NEOPLASMS; VERY ELDERLY;

ADMINISTRATION, INTRAVESICAL; AGED; AGED, 80 AND OVER; ANIMALS; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOTHERAPY; KAPLAN-MEIER ESTIMATE; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; URINARY BLADDER NEOPLASMS;

EID: 84908357006     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.02.061     Document Type: Article

References (32)

1. S. Brandau, and H. Suttmann Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement Biomed Pharmacother 61 2007 299 305
2. H.W. Herr, and A. Morales History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story J Urol 179 2008 53 56
3. M.A. Behr, M.A. Wilson, and W.P. Gill et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray Science 284 1999 1520 1523
4. R. Brosch, S.V. Gordon, and T. Garnier et al. Genome plasticity of BCG and impact on vaccine efficacy Proc Natl Acad Sci U S A 104 2007 5596 5601
5. M.A. Behr BCG - different strains, different vaccines? Lancet Infect Dis 2 2002 86 92
6. K.F. Schulz, D.G. Altman, and D. Moher CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials PLoS Med 7 2010 e10000251
7. W. Van den Broeck, A. Derore, and P. Simoens Anatomy and nomenclature of murine lymph nodes: descriptive study and nomenclatory standardization in BALB/cAnNCrl mice J Immunol Methods 312 2006 12 19
8. H. Li, J. Ruan, and R. Durbin Mapping short DNA sequencing reads and calling variants using mapping quality scores Genome Res 18 2008 1851 1858
9. D.R. Zerbino, and E. Birney Velvet: algorithms for de novo short read assembly using de Bruijn graphs Genome Res 18 2008 821 829
10. K. Arnold, L. Bordoli, J. Kopp, and T. Schwede The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling Bioinformatics 22 2006 195 201
11. C. Biot, C.A. Rentsch, and J.R. Gsponer et al. Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer Sci Transl Med 4 2012 137ra72
12. S.M. Irwin, A.A. Izzo, and S.W. Dow et al. Tracking antigen-specific CD8 T lymphocytes in the lungs of mice vaccinated with the Mtb72F polyprotein Infect Immun 73 2005 5809 5816
13. P. Bousso, A. Casrouge, and J.D. Altman et al. Individual variations in the murine T cell response to a specific peptide reflect variability in naive repertoires Immunity 9 1998 169 178
14. J.P. Klein, B. Logan, M. Harhoff, and P.K. Andersen Analyzing survival curves at a fixed point in time Stat Med 26 2007 4505 4519
15. Y. Pan, X. Yang, and J. Duan et al. Whole-genome sequences of four Mycobacterium bovis BCG vaccine strains J Bacteriol 193 2009 3152 3153
16. L.H. Gomes, T.D. Otto, and E.A. Vasconcellos et al. Genome sequence of Mycobacterium bovis BCG Moreau, the Brazilian vaccine strain against tuberculosis J Bacteriol 193 2011 5600 5601
17. M. Seki, I. Honda, and I. Fujita et al. Whole genome sequence analysis of Mycobacterium bovis bacillus Calmette-Guerin (BCG) Tokyo 172: a comparative study of BCG vaccine substrains Vaccine 27 2009 1710 1716
18. P. Orduna, M.A. Cevallos, and S.P. de Leon et al. Genomic and proteomic analyses of Mycobacterium bovis BCG Mexico 1931 reveal a diverse immunogenic repertoire against tuberculosis infection BMC Genomics 12 2011 493
19. L. Spagnolo, I. Toro, and M. D'Orazio et al. Unique features of the sodC-encoded superoxide dismutase from Mycobacterium tuberculosis, a fully functional copper-containing enzyme lacking zinc in the active site J Biol Chem 279 2004 33447 33455
20. B. Zbar, and H.J. Rapp Immunotherapy of guinea pig cancer with BCG Cancer 34 Suppl 1974 1532 1540
21. D.L. Lamm, B.A. Blumenstein, and J.D. Crissman et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study J Urol 163 2000 1124 1129
22. M. Burger, J.W. Catto, and G. Dalbagni et al. Epidemiology and risk factors of urothelial bladder cancer Eur Urol 63 2013 234 241
23. P.D. Vegt, J.A. Witjes, and W.P. Witjes et al. A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder J Urol 153 1995 929 933
24. W.P. Witjes, J.A. Witjes, G.O. Oosterhof, and M.J. Debruyne Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guerin-Tice versus bacillus Calmette-Guerin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group Semin Urol Oncol 14 1996 10 16
25. N. Ritz, B. Dutta, and S. Donath et al. The influence of bacille Calmette-Guerin vaccine strain on the immune response against tuberculosis: a randomized trial Am J Respir Crit Care Med 185 2011 213 222
26. M.R. Lagranderie, A.M. Balazuc, E. Deriaud, C.D. Leclerc, and M. Gheorghiu Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains Infect Immun 64 1996 1 9
27. S.M. Irwin, A. Goodyear, and A. Keyser et al. Immune response induced by three Mycobacterium bovis BCG substrains with diverse regions of deletion in a C57BL/6 mouse model Clin Vaccine Immunol 15 2008 750 756
28. A.I. Castillo-Rodal, M. Castanon-Arreola, and R. Hernandez-Pando et al. Mycobacterium bovis BCG substrains confer different levels of protection against Mycobacterium tuberculosis infection in a BALB/c model of progressive pulmonary tuberculosis Infect Immun 74 2006 1718 1724
29. R.J. Sylvester, M.A. van der, and D.L. Lamm Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials J Urol 168 2002 1964 1970
30. D.L. Piddington, F.C. Fang, and T. Laessig et al. Cu,Zn superoxide dismutase of Mycobacterium tuberculosis contributes to survival in activated macrophages that are generating an oxidative burst Infect Immun 69 2001 4980 4987
31. O. Dussurget, G. Stewart, and O. Neyrolles et al. Role of Mycobacterium tuberculosis copper-zinc superoxide dismutase Infect Immun 69 2001 529 533
32. A. Sengiku, M. Ito, and Y. Miyazaki et al. A prospective comparative study of intravesical bacillus Calmette-Guerin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer J Urol 190 2013 50 54